ADC Therapeutics SA (ADCT)
| Previous Close | 4.4500 |
| Open | 4.4000 |
| Bid | 4.7600 x 900 |
| Ask | 4.7800 x 1400 |
| Day's Range | 4.3397 - 4.9100 |
| 52 Week Range | 0.3600 - 6.0400 |
| Volume | |
| Avg. Volume | 636,227 |
| Market Cap | 396.679M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9400 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.20 |
Insider MonkeyADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript May 6, 2024 ADC Therapeutics SA reports earnings inline with expectations. Reported EPS is $-0.56 EPS, expectations were $-0.56. ADCT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and […]
GlobeNewswireADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross procee
ZacksADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
